Please Wait.....
Report
Global Myasthenia Gravis Treatment Market: Forecast and Trends
Market Research Report I 2023-11-23 I 120 Pages I BCC Research
Description
Report Scope:
This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.
Report Includes:
- 54 data tables and 47 additional tables
- An overview and analysis of the global market for myasthenia gravis (MG) treatments
- Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
- In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
- Analysis of the market growth opportunities through Porter's Five Forces and PESTLE analyses, taking into consideration the prevailing micro- and macro environmental factors
- An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
- Discussion of the factors driving the market, industry trends and new developments
- Analysis of relevant patents
- Identification of the leaders in the field of MG
- Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva
Executive Summary
Summary:
The market for myasthenia gravis (myasthenia gravis) treatments had an estimated value of $REDACTED billion in 2022 and is projected to grow to $REDACTED billion in 2028.
The global market for myasthenia gravis treatments was valued at nearly $REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED%, reaching $REDACTED billion in 2028. Growth in this market is fueled by a worldwide increase in elderly populations and an increased prevalence of myasthenia gravis.
Technological innovation is an important catalyst driving adaptation and use.
In 2022, the generalized myasthenia gravis segment held the highest market share at about REDACTED%, followed by ocular myasthenia gravis at REDACTED% and transient neonatal myasthenia gravis at REDACTED%
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Report Highlights
Chapter 3 Market Overview
Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
North America
Europe
Asia-Pacific
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications
Surgery
Intravenous (IV) Therapy
Medications
Chapter 4 Market Dynamics
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine
Market Opportunities
Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration
Market Restraints
Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies
Other Restraints
Chapter 5 Market Breakdown by Region
Market Overview
North America
Europe
Asia-Pacific
Chapter 6 Market Breakdown by Type
Market Overview
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Ocular Myasthenia Gravis
Chapter 7 Market Breakdown by Treatment Modality
Introduction
Medications
Surgery
Intravenous Therapy
Chapter 8 Market Breakdown by Type of Product
Monoclonal Antibodies
Brands
Cholinesterase Inhibitors
Brand
Intravenous Immunoglobulins
Brands
Immunosuppressants
Brand
Corticosteroids
Brand
Chapter 9 ESG Development
Introduction
Environment
Social
Governance
Case Study
AstraZeneca
Concluding Remarks from BCC Research
Chapter 10 Emerging Technologies and Developments
Introduction
Chapter 11 Competitive Intelligence
Overview
Industry Scenario
Company Shares
Chapter 12 Patent Analysis
Patent Analysis by Manufacturer
Chapter 13 Pipeline Analysis
Clinical Trials
Chapter 14 M&A and Venture Funding Outlook
Introduction
Chapter 15 Company Profiles
ABBVIE
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB
CSL
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 16 Appendix: Acronyms
List of Tables
Summary Table : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : Factors Leading to the Increasing Incidence of Myasthenia Gravis Worldwide
Table 3 : Global Serological Testing for Myasthenia Gravis, by Type
Table 4 : Targeted Drug Therapies for the Treatment of Myasthenia Gravis
Table 5 : Diagnostic Challenges in the Treatment of Myasthenia Gravis
Table 6 : Risks of Emerging Therapies for Myasthenia Gravis, by Type
Table 7 : Global Market for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 8 : North American Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 9 : European Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 10 : Asia-Pacific Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 11 : Global Prevalence of Myasthenia Gravis, by Type
Table 12 : Global Market for the Treatment of Generalized Myasthenia Gravis, by Region, Through 2028
Table 13 : Global Market for the Treatment of Ocular Myasthenia Gravis, by Region, Through 2028
Table 14 : Global Market for the Treatment of Transient Neonatal Myasthenia Gravis, by Region, Through 2028
Table 15 : Global Market for Medications for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 16 : Global Market for Surgical Treatment of Myasthenia Gravis, by Region, Through 2028
Table 17 : Global Market for Intravenous Therapy for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 18 : Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 19 : Global Market for Monoclonal Antibodies for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 20 : Global Market for Cholinesterase Inhibitors for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 21 : Global Market for Intravenous Immunoglobulins for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 22 : Global Market for Immunosuppressants for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 23 : Global Market for Corticosteroids for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 24 : ESG Framework for the Global Pharmaceutical Industry
Table 25 : Social Framework of the Global Pharmaceutical Industry
Table 26 : Top Pharma Companies: ESG Ratings
Table 27 : AstraZeneca's Contribution to Sustainable Development Goals
Table 28 : AstraZeneca's Material Focus Areas
Table 29 : New Technologies for Myasthenia Gravis Treatments
Table 30 : New Pharmaceuticals for the Treatment of Myasthenia Gravis
Table 31 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Table 32 : Global Product Shares of Myasthenia Gravis Treatments, by Brand, 2022
Table 33 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Table 34 : Key Financials of Pharma Companies Offering Myasthenia Gravis Treatment Products, 2022
Table 35 : Patents on Myasthenia Gravis Treatments, 2018-Present
Table 36 : Selected Manufacturer Patents on Myasthenia Gravis Drugs, 2018-Present
Table 37 : Patents on Eculizumab, 2018-Present
Table 38 : Selected Manufacturer Patents on Eculizumab, 2018-Present
Table 39 : Patents on Efgartigimod alfa, 2018-Present
Table 40 : Selected Manufacturer Patents on Efgartigimod alfa, 2018-Present
Table 41 : Patents on Rituximab, 2018-Present
Table 42 : Selected Manufacturer Patents on Rituximab, 2018-Present
Table 43 : Patents on Pyridostigmine, 2018-Present
Table 44 : Selected Manufacturer Patents on Pyridostigmine, 2018-Present
Table 45 : Patents on Privigen, 2018-Present
Table 46 : Selected Manufacturer Patents on Privigen, 2018-Present
Table 47 : Clinical Trials on Myasthenia Gravis, as of 2023
Table 48 : Mergers and Acquisitions, 2019-2021
Table 49 : AbbVie: Product Information
Table 50 : AbbVie: Financial Overview, 2020-2022
Table 51 : AbbVie: Key Developments, 2021-2023
Table 52 : Amgen: Revenue, 2020-2022
Table 53 : Amgen: Key Developments, 2021 and 2022
Table 54 : Astellas Pharma: Revenue, 2020-2022
Table 55 : Astellas Pharma: Key Developments, 2018-2022
Table 56 : AstraZeneca: Product Information
Table 57 : AstraZeneca: Revenue, 2020-2022
Table 58 : AstraZeneca: Key Developments, 2022 and 2023
Table 59 : Bausch Health: Product Information
Table 60 : Bausch Health: Revenue, 2020-2022
Table 61 : Bayer AG: Product Information
Table 62 : Bayer AG: Financial Overview, 2020-2022
Table 63 : Bayer AG: Key Developments, 2022 and 2023
Table 64 : Biogen: Financial Overview, 2020-2022
Table 65 : Biogen: Key Developments, 2018-2023
Table 66 : Bristol-Myers Squibb: Product Information
Table 67 : Bristol-Myers Squibb: Financial Overview, 2020-2022
Table 68 : Bristol-Myers Squibb: Key Developments, 2021-2023
Table 69 : CSL: Product Information
Table 70 : CSL: Revenue, 2020-2022
Table 71 : CSL: Recent Developments, 2022
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Financial Overview, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Roche: Product Information
Table 76 : Roche: Revenue, 2020-2022
Table 77 : Roche: Key Developments, 2021-2023
Table 78 : Gilead Sciences: Financial Overview, 2020-2022
Table 79 : Gilead Sciences: Key Developments, 2022
Table 80 : GlaxoSmithKline plc: Product Segments
Table 81 : GlaxoSmithKline plc: Financial Overview, 2020-2022
Table 82 : GlaxoSmithKline plc: Recent Developments, 2022
Table 83 : Merck & Co. Inc.: Business Segments
Table 84 : Merck & Co. Inc.: Financial Overview, 2020-2022
Table 85 : Merck & Co. Inc.: Key Developments, 2022
Table 86 : Novartis: Product Information
Table 87 : Novartis: Financial Overview, 2020-2022
Table 88 : Novartis: Key Developments, 2023
Table 89 : Pfizer Inc: Product Segments
Table 90 : Pfizer Inc: Financial Overview, 2020-2022
Table 91 : Pfizer Inc: Top Brands, 2022
Table 92 : Pfizer Inc: Key Developments, 2019-2023
Table 93 : Sanofi: Business Segments
Table 94 : Sanofi: Annual Revenue, 2020-2022
Table 95 : Sanofi: Key Developments, 2021-2023
Table 96 : Servier: Annual Revenue, 2020-2022
Table 97 : Servier: Key Developments, 2022 and 2023
Table 98 : Teva: Financial Overview, 2020-2022
Table 99 : Teva: Key Developments, 2021-2023
Table 100 : Acronyms
List of Figures
Summary Figure A : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2020-2028
Summary Figure B : Global Market Shares of the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2022
Figure 1 : Global Factors Leading to the Prevalence of Myasthenia Gravis, by Region, 2022
Figure 2 : Global Market Shares of Myasthenia Gravis Treatments, by Region, 2022
Figure 3 : North American Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 4 : European Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 5 : Asia-Pacific Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 6 : Global Distribution of Types of Myasthenia Gravis, 2022
Figure 7 : Global Market Shares of Myasthenia Gravis Treatments, by Treatment Modality, 2022
Figure 8 : Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, Through 2022
Figure 9 : Global Electricity Production from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO2 Emissions, 2017-2021
Figure 12 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Figure 13 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Figure 14 : AbbVie: Revenue Shares, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Country/Region, 2022
Figure 17 : Gilead Sciences: Revenue, by Type of Product, 2022
Figure 18 : GlaxoSmithKline plc: Annual Revenue, by Segment, 2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, Pharmaceutical Segment, 2022
Figure 20 : Novartis Innovative Medicines: Market Share, by Country/Region, 2022
Figure 21 : Novartis Sandoz: Market Share, by Country/Region 2022
Figure 22 : Sanofi: Revenue, by Region, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security